| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5537734 | Vaccine | 2016 | 7 Pages |
Abstract
Given that high IgG titers were achieved and maintained after PCV13 vaccination, and considering the high morbidity related to S. pneumoniae, we propose PCV13 (re-)vaccination for all NS patients, irrespective of their previous immunization history, treatment and disease activity.
Keywords
PCV13FSGSPPSV23IPDPCV7IQROPAIgGEnzyme-linked immunosorbent assay (ELISA)Streptococcus pneumoniaestandard deviationImmunizationimmunoglobulin Gminimal change diseaseInvasive pneumococcal diseaseEnzyme-linked immunosorbent assayELISAnephrotic syndromeconfidence intervalMonthinterquartile rangeodds ratioAIMVaccine7-valent pneumococcal conjugate vaccinePneumococcal conjugate vaccine23-Valent pneumococcal polysaccharide vaccine13-Valent pneumococcal conjugate vaccinePCV یا Pneumococcal conjugate vaccineFocal segmental glomerulosclerosis
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Laure F. MD, Klara M. MD, MS, Hassib MD, Christoph MD, Alexandra MD, Maria Rodriguez, Claire-Anne MD, Paloma MD,